Harbour Investments
ALXN

Harbour Investments’s Alexion Pharmaceuticals ALXN Stock Holding History

Harbour Investments’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-390
Closed -$72K – 4149
2021
Q2 		$72K Sell
390
-2
-0.5% -$343 ﹤0.01% 1593
2021
Q1 		$60K Buy
+392
New +$60.6K ﹤0.01% 1589

Other funds holding ALXN

Brinker Capital Investments
Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return
TD Ameritrade Investment Management
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Harbour Investments's ALXN Position: Q3 2021 in Review

Harbour Investments sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 390 shares — an estimated $72K sold.

Harbour Investments first reported a position in ALXN in Q1 2021 and held it in 2 quarters. The position peaked at $72K in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Harbour Investments reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Harbour Investments sold 390 Alexion Pharmaceuticals shares in Q3 2021, an estimated $72K.
  • Harbour Investments first reported a position in Alexion Pharmaceuticals in Q1 2021 and held it in 2 quarters.
  • Harbour Investments's Alexion Pharmaceuticals position peaked at $72K in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Harbour Investments's 13F filing for Q3 2021, filed 15 Nov 2021.